OATD-01 (GLPG-4716), a dual inhibitor of acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1), is in early clinical trials at Molecure (formerly OncoArendi Therapeutics) for the oral treatment of diseases with a fibrotic component such as idiopathic pulmonary fibrosis (IPF) and sarcoidosis.
In 2020, OncoArendi Therapeutics granted the global rights of development and commercialization to Galapagos. In 2022, Galapagos returned all product rights.
The compound was granted orphan drug designation in the U.S. for the treatment of IPF and for the treatment of sarcoidosis in 2019 and 2020, respectively.
For research use only. We do not sell to patients.